PDCD1 and neoplasm: Consistently, we observed a more distinct immune phenotype at S2 tumours with reduced GZMB (granzyme B) and enriched PDCD1 (PD-1), FOXP3 and CTLA4 compared to N or S1 and S3 tumours (Fig. 3a).